Scarica l'app Stockscreener
18.11
1.58%
-0.29
Dopo l'orario di chiusura:
18.40
0.29
+1.60%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DNLI Giù?
Forum
Previsione
Precedente Chiudi:
$18.40
Aprire:
$18.39
Volume 24 ore:
2.13M
Relative Volume:
1.23
Capitalizzazione di mercato:
$2.87B
Reddito:
$1.27M
Utile/perdita netta:
$-512.54M
Rapporto P/E:
-6.0995
EPS:
-2.9691
Flusso di cassa netto:
$-422.10M
1 W Prestazione:
-6.94%
1M Prestazione:
-11.96%
6M Prestazione:
+7.03%
1 anno Prestazione:
+30.19%
Intervallo 1D:
$17.71
$18.40
Intervallo di 1 settimana:
$17.71
$20.00
Portata 52W:
$12.58
$23.77
Denali Therapeutics Inc Stock (DNLI) Company Profile
Nome
Denali Therapeutics Inc
Settore
Industria
Telefono
(650) 866-8547
Indirizzo
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO
Compare DNLI vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DNLI
Denali Therapeutics Inc
|
18.11 | 2.92B | 1.27M | -512.54M | -422.10M | -2.9691 |
VRTX
Vertex Pharmaceuticals Inc
|
434.31 | 110.81B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
630.30 | 66.02B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
797.77 | 48.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.30 | 38.22B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
147.30 | 30.69B | 742.00K | -1.37B | -1.07B | -7.0731 |
Denali Therapeutics Inc Stock (DNLI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-26 | Reiterato | H.C. Wainwright | Buy |
| 2026-02-24 | Iniziato | Wolfe Research | Peer Perform |
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-04-10 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2025-03-07 | Ripresa | Morgan Stanley | Overweight |
| 2025-02-11 | Iniziato | Deutsche Bank | Buy |
| 2025-01-07 | Iniziato | Robert W. Baird | Outperform |
| 2025-01-03 | Iniziato | William Blair | Outperform |
| 2024-12-16 | Aggiornamento | Stifel | Hold → Buy |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-10-07 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-12-13 | Iniziato | Citigroup | Buy |
| 2023-11-20 | Ripresa | JP Morgan | Overweight |
| 2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-09-06 | Iniziato | B. Riley Securities | Buy |
| 2023-01-30 | Iniziato | SVB Securities | Outperform |
| 2022-12-05 | Iniziato | Cowen | Outperform |
| 2022-11-02 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-11-02 | Iniziato | BofA Securities | Buy |
| 2022-06-23 | Iniziato | Berenberg | Buy |
| 2021-12-10 | Ripresa | Raymond James | Mkt Perform |
| 2021-09-21 | Iniziato | Oppenheimer | Outperform |
| 2021-09-01 | Iniziato | SMBC Nikko | Outperform |
| 2021-05-18 | Iniziato | UBS | Buy |
| 2021-02-26 | Reiterato | H.C. Wainwright | Buy |
| 2021-02-10 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-11-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-16 | Downgrade | BTIG Research | Buy → Neutral |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-08-20 | Reiterato | H.C. Wainwright | Buy |
| 2020-03-13 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2020-02-28 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2020-02-24 | Iniziato | Jefferies | Buy |
| 2020-02-19 | Iniziato | Stifel | Hold |
| 2020-01-27 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-09-26 | Iniziato | Wedbush | Neutral |
| 2019-09-13 | Iniziato | Nomura | Buy |
| 2019-08-09 | Iniziato | BTIG Research | Buy |
| 2019-06-26 | Iniziato | H.C. Wainwright | Buy |
| 2018-11-15 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-11-12 | Iniziato | Janney | Buy |
| 2018-03-12 | Downgrade | Evercore ISI | Outperform → In-line |
| 2018-01-02 | Iniziato | Evercore ISI | Outperform |
| 2018-01-02 | Iniziato | Goldman | Neutral |
| 2018-01-02 | Iniziato | JP Morgan | Overweight |
| 2018-01-02 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Denali Therapeutics Inc Borsa (DNLI) Ultime notizie
DNLI Q1 loss narrower than expected, Avlayah approval boosts prospects - MSN
Hedge Fund Wagers $36 Million on Biotech Denali After First FDA Approval - Yahoo Finance
DNLI gains 25.4% year to date: Should you buy, sell or hold the stock? - MSN
Denali Therapeutics Says AVLAYAH Launch Ahead of Expectations After Hunter Syndrome Approval - MarketBeat
T. Rowe Price holds 5.4% of Denali Therapeutics (NASDAQ: DNLI) - Stock Titan
Biogen’s Alzheimer’s results bolster tau theory—and Denali’s next gen candidate - BioSpace
DNLI Stock Price, Quote & Chart | DENALI THERAPEUTICS INC (NASDAQ:DNLI) - ChartMill
FDA clears Denali Therapeutics drug as first brain-penetrating biologic for rare disease - MSN
Oligonucleotides Clinical Trial Drug Development Pipeline Expands with Contributions from 200+ Key Companies | DelveInsight - The Manila Times
Oligonucleotides Clinical Trial Drug Development Pipeline Expands with Contributions from 200+ Key Companies | DelveInsight - GlobeNewswire Inc.
Morgan Stanley Trims Price Target on Denali Therapeutics to $40 From $42, Keeps Overweight Rating - Moomoo
Morgan Stanley Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Cuts Target Price to $40 - Moomoo
Denali Therapeutics stock (US24823R1077): Takeda exits DNL593 partnership - AD HOC NEWS
Number of shareholders of Denali Therapeutics Inc. – SWB:4DN - TradingView
MSN Money - MSN
The Technical Signals Behind (DNLI) That Institutions Follow - Stock Traders Daily
Denali Therapeutics stock (US24823R1077): FDA priority review for Hunter syndrome drug - AD HOC NEWS
HC Wainwright Issues Optimistic Outlook for DNLI Earnings - MarketBeat
A Look At Denali Therapeutics (DNLI) Valuation After Accelerated FDA Approval Of AVLAYAH - Sahm
Oppenheimer Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $40 - Moomoo
BTIG Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $39 - Moomoo
Denali Therapeutics Seeing Encouraging Signals From Avlayah Launch, Oppenheimer Says - Moomoo
Denali Therapeutics (NASDAQ:DNLI) Earns "Buy" Rating from BTIG Research - MarketBeat
TradingKey - TradingKey
Denali Therapeutics (NASDAQ:DNLI) Stock Rating Upgraded by Wall Street Zen - MarketBeat
Wedbush Adjusts Denali Therapeutics Price Target to $23 From $25, Maintains Outperform Rating - Moomoo
William Blair Maintains Denali Therapeutics(DNLI.US) With Buy Rating - Moomoo
DNLI Q1 Loss Narrower Than Expected, Avlayah Approval Boosts Prospects - Eastern Progress
Denali Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Denali Therapeutics (NASDAQ: DNLI) adds cash on AVLAYAH deal despite Q1 loss - Stock Titan
Denali Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
FDA-approved Hunter syndrome drug reaches first U.S. patients - Stock Titan
Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights - The Manila Times
Denali Therapeutics (DNLI) wins FDA nod for AVLAYAH and ends Q1 2026 with $1.05B cash - Stock Titan
Nancy Pelosi Stock Tracker Highlights Claude's Pharma Earnings Play: 'Will Be Interesting To See How This - Benzinga
FMR LLC increases visibility on Denali (DNLI): 6.67M shares disclosed - Stock Titan
Privium Fund Opens $5.07 Million Denali Stake Ahead of FDA Drug Approval - AOL.com
Assessing Denali Therapeutics (DNLI) Valuation After Takeda Ends DNL593 Partnership - Sahm
Denali Therapeutics (DNLI) Expected to Announce Quarterly Earnings on Monday - MarketBeat
Why Denali Therapeutics (DNLI) Is Down 8.2% After Takeda Exits DNL593 Collaboration And Returns Rights - Yahoo Finance
D.A. Davidson & CO. Invests $1.77 Million in Denali Therapeutics Inc. $DNLI - MarketBeat
Denali: The First Commercial Validation Of The Blood-Brain Barrier Platform - Seeking Alpha
Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Japanese Stocks Amid Restructuring Drive? - Yahoo Finance
Precision Trading with Denali Therapeutics Inc. (DNLI) Risk Zones - Stock Traders Daily
Denali Therapeutics Inc. $DNLI Shares Bought by Pictet Asset Management Holding SA - MarketBeat
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Denali Therapeutics Inc Azioni (DNLI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.19%
0.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):